PrenaTest STANDARD 3 (trisomy 21/13/18 and gonosome aneuploidy )
8 days Prenatest Standard 3 (Trisomy 21/13/18 And Gonosome Aneuploidy)
We remind you that independent interpretation of the results is unacceptable, the information provided below is for reference purposes only.
Prenatest Standard 3 is a non-invasive prenatal test (NIPT) that screens for trisomies 21 (Down syndrome), 13 (Patau syndrome), and 18 (Edwards syndrome), as well as gonosomal aneuploidies (sex chromosome abnormalities). This test analyzes cell-free DNA (cfDNA) from the placenta, which is present in the mother's bloodstream during pregnancy.
The Importance of Prenatal Screening
Prenatal screening tests aim to identify potential chromosomal abnormalities or genetic disorders in the developing fetus. Early detection can help expectant parents make informed decisions and prepare for any necessary medical interventions or support services.
Table 1: Conditions Screened by Prenatest Standard 3
| Condition | Description |
|---|---|
| Trisomy 21 (Down syndrome) | An extra copy of chromosome 21, leading to developmental delays and intellectual disabilities. |
| Trisomy 13 (Patau syndrome) | An extra copy of chromosome 13, associated with severe intellectual disabilities and physical abnormalities. |
| Trisomy 18 (Edwards syndrome) | An extra copy of chromosome 18, often resulting in severe developmental delays and life-threatening medical issues. |
| Gonosomal Aneuploidies | Abnormalities in the number of sex chromosomes (X and Y), such as Turner syndrome and Klinefelter syndrome. |
Prenatest Standard 3 provides valuable insights into the potential risk of these chromosomal conditions, allowing healthcare providers and expectant parents to make informed decisions about further diagnostic testing or preparation for the birth and care of a child with special needs.
Role of Prenatest Standard 3 (Trisomy 21/13/18 And Gonosome Aneuploidy) in Diagnosis
Prenatest Standard 3 (Trisomy 21/13/18 And Gonosome Aneuploidy) is a non-invasive prenatal screening test that analyzes cell-free DNA (cfDNA) from the mother's blood to assess the risk of certain chromosomal abnormalities in the fetus. This test plays a crucial role in detecting trisomies 21 (Down syndrome), 18 (Edwards syndrome), and 13 (Patau syndrome), as well as sex chromosome aneuploidies.
Indications for Ordering the Test
The Prenatest Standard 3 (Trisomy 21/13/18 And Gonosome Aneuploidy) test is typically recommended for pregnant women who meet the following criteria:
- Advanced maternal age (typically over 35 years old)
- Positive results from other prenatal screening tests
- Family history of chromosomal abnormalities
- Ultrasound findings that suggest potential chromosomal abnormalities
- Previous pregnancy with a chromosomal abnormality
This non-invasive prenatal screening test provides valuable information to healthcare providers and expectant parents, assisting in the early detection of potential chromosomal abnormalities and guiding further diagnostic testing if necessary.
Preparation for the Procedure
Preparing for the Prenatest Standard 3 (Trisomy 21/13/18 And Gonosome Aneuploidy) analysis typically involves the following steps:
- No specific dietary restrictions are required, but maintaining a balanced diet is recommended.
- Avoid strenuous physical activity or exercise on the day of the test.
- Inform your healthcare provider about any medications or supplements you are taking, as some may affect the test results.
- Stay well-hydrated by drinking plenty of fluids before the test to facilitate the blood draw process.
The Procedure
The Prenatest Standard 3 (Trisomy 21/13/18 And Gonosome Aneuploidy) analysis involves a simple blood draw, typically from a vein in the arm. A trained healthcare professional will perform the venipuncture, and the process usually takes a few minutes. After the blood draw, you may experience minor bruising or discomfort at the puncture site, which should resolve within a few days.
How the Test is Performed
The Prenatest Standard 3 is a non-invasive prenatal screening test that analyzes cell-free DNA (cfDNA) from the placenta in a pregnant woman's blood sample. It is designed to detect the risk of certain chromosomal abnormalities, such as Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome), as well as sex chromosome aneuploidies.
The test involves taking a small blood sample from the pregnant woman, typically after the 10th week of gestation. The cfDNA is then isolated from the plasma and analyzed using advanced sequencing technologies to determine the relative amounts of chromosomal material present. This information is used to calculate the risk of the tested chromosomal conditions.
It is important to note that this test is a screening method and does not provide a definitive diagnosis. If the test indicates an increased risk, follow-up diagnostic testing, such as chorionic villus sampling (CVS) or amniocentesis, may be recommended to confirm the results.
Sources:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991414/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395059/
https://my.clevelandclinic.org/health/diseases/24060-aneuploidy
https://www.webmd.com/baby/your-guide-prenatal-testing
IMPORTANT!
It is essential to remember that the information provided in this section is not intended for self-diagnosis or self-treatment. If you experience any symptoms or a flare-up of a condition, it is crucial to consult a healthcare professional for proper diagnostic testing and treatment. Only a qualified specialist can provide an accurate diagnosis and determine the appropriate treatment plan. To ensure the most accurate and consistent evaluation of test results, it is recommended to have them performed at the same laboratory. This is because different laboratories may use varying methods and units of measurement for similar tests.
You may also be interested in:
7 days 7 days 7 days 8 days 
